FO
BCRX icon

FT Options’s BioCryst Pharmaceuticals BCRX Stock Holding History

FT Options’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-71,700
Closed -$179K – 198
2017
Q1 		$179K Buy
+71,700
New +$499K 0.24% 84
2016
Q1 		– Sell
-9,100
Closed -$3K – 293
2015
Q4 		$3K Buy
+9,100
New +$90.5K ﹤0.01% 193

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FT Options's BCRX Position: Q3 2017 in Review

FT Options sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 11,240 shares — an estimated $62K sold.

FT Options first reported a position in BCRX in Q4 2015 and held it in 2 quarters. The position peaked at $409K in Q4 2015. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

  • FT Options reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • FT Options sold 11,240 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $62K.
  • FT Options first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • FT Options's BioCryst Pharmaceuticals position peaked at $409K in Q4 2015.
  • 120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.